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Dear editor
As the scientific steering committee for THALASSA (an assessment of Exjade in 
nontransfusion-dependent thalassemia [NTDT]), we read with interest the review by 
Kontoghiorghe and Kontoghiorghes entitled “Efficacy and safety of iron-chelation 
therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded 
patients with non-transfusion-dependent thalassemia syndromes” published in January 
2016.1 While this review provides a detailed overview of available iron chelators for 
the treatment of NTDT patients, there remain some factual inaccuracies and misrepre-
sentations of data related to deferasirox. Therefore, we believe that the current article 
may be misleading to readers of Drug Design, Development and Therapy.
Foremost, there is no mention that to date deferasirox is the only oral iron chelator 
approved for the treatment of chronic iron overload in NTDT patients. Approval was 
granted following the successful THALASSA trial (n=166), the first randomized, 
controlled study showing that deferasirox significantly reduces iron overload in NTDT 
patients with a manageable safety profile.2,3 As such, we feel that the recommendation 
by Kontoghiorghe and Kontoghiorghes for deferiprone as the first-line treatment of 
NTDT patients is concerning given the absence of robust clinical evidence and regu-
latory approval. Indeed, deferiprone is recommended as a second-line treatment in 
most clinical practice guidelines worldwide. Furthermore, the authors draw many of 
their conclusions regarding deferasirox tolerability from postmarketing surveillance 
information, yet neglect to mention premarketing clinical trial experience from ~700 
adult/pediatric patients supporting a clinically manageable safety profile for deferasirox 
with appropriate patient monitoring.4 Both sources of data should be considered for a 
balanced analysis of drug-related tolerability issues.
There are also several specific claims regarding deferasirox that we would like to 
highlight as inaccurate and provide further supportive evidence to the contrary:
•	 “DFX appears to increase iron and other toxic metal absorption.” Concerns about 
the increased iron uptake were addressed during the development of deferasirox 
and were shown not to occur.5 Given the structural similarities between iron–
deferasirox and aluminum–deferasirox complexes,6 increased gastrointestinal 
uptake of aluminum would not be anticipated in vivo. These data were neither 
discussed nor cited.
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•	 “[…] excess iron removal from the heart by DFX is not 
effective and in most cases very slow, with no improve-
ment in LVEF, especially in heavily iron-loaded TM 
patients.” Clinical evidence for deferasirox in the 
removal of cardiac iron has been demonstrated in the 
large, prospective EPIC cardiac substudy and the ran-
domized CORDELIA study.7,8 Deferasirox was effec-
tive in removing cardiac iron and maintaining cardiac 
function in thalassemia patients with mild, moderate, 
and severe cardiac siderosis. Furthermore, in CORD-
ELIA, although the enrolled patients had left ventricular 
ejection fraction $56% at baseline, small improvements 
were noted in some patients.8,9 This is important because 
even small improvements can reduce the risk of heart 
failure.10
•	 “The use of DFX is not recommended for iron-loaded 
patients with serum ferritin lower than 500 ng/mL.” 
The authors cite deferasirox-labeling information from 
2010, prior to updates in 2015 that include the indication 
of deferasirox for NTDT patients. In the 2015 version, 
treatment interruptions are indicated when serum ferritin 
is ,300 ng/mL, the safety of which was established in 
THALASSA.4,11
•	 “Lower efficacy and higher toxicity was reported for 
DFX in TI […] by investigators not related or funded 
by the manufacturers of DFX.” This statement is based 
on one retrospective, single-center study of a combined 
population of β-thalassemia major and intermedia 
patients.12 The cited study by Karimi et al13 was an 
independent study, and there are additional investigator-
initiated studies14,15 that were not cited. Together with 
the outcomes of THALASSA, results from these studies 
provide credible evidence supporting the efficacy and 
safety of deferasirox in NTDT patients.
•	 “DFX is also very expensive and cannot be afforded by 
the vast majority of patients.” Here, there is no mention 
of cost-effectiveness analyses by Karnon et al16 who have 
demonstrated that the higher drug cost of deferasirox may 
be offset by savings due to the cost of DFO administration 
(eg, pumps and needles) or the reduced need to treat iron 
overload-related complications that can develop when 
patients are not compliant with DFO.
Finally, we feel it necessary to inform readers that Dr 
Kontoghiorghes has a conflict of interest in deferiprone, 
which has not been declared. Dr Kontoghiorghes was a 
member of the team who first synthesized deferiprone and 
has subsequently been described as the discoverer (eg, http://
www.pri.ac.cy/research.htm).
We hope this letter clarifies some of the misconceptions 
presented by Kontoghiorghe and Kontoghiorghes and will 
provide physicians with additional information for consid-
eration when deciding upon the most appropriate treatment 
for their patients.
Acknowledgments
The THALASSA trial was funded by Novartis Pharma AG. 
We thank Rebecca Helson, PhD, of Mudskipper Business 
Ltd for medical editorial assistance. Financial support for 
medical editorial assistance was provided by Novartis Phar-
maceuticals Corporation.
Disclosure
ATT reports receiving research funding and honoraria from 
Novartis. JBP reports consultancy, receiving research grant 
funding and honoraria from Novartis, consultancy and 
honoraria from Shire, and consultancy for Celgene. JBP is 
supported by the NIHR University College London Hospitals 
Biomedical Research Centre (BRC). AK reports participa-
tion in advisory boards and educational forums sponsored 
by Novartis and Apopharma and receiving research funding 
from Novartis. VV received research grant support and lec-
ture fees from Novartis, Genzyme-Sanofi, Sebia, and Roche 
Diagnostics and research grant support from Shire, Sideris 
and Faculty of Medicine, Siriraj Hospital, Thailand. MDC 
reports receiving honoraria from Novartis, Genzyme, and 
Celgene. The authors report no other conflicts of interest 
in this work.
References
1. Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-
chelation therapy with deferoxamine, deferiprone, and deferasirox for 
the treatment of iron-loaded patients with non-transfusion-dependent 
thalassemia syndromes. Drug Des Devel Ther. 2016;10:465–481.
2. Taher AT, Porter J, Viprakasit V, et al. Deferasirox significantly reduces 
iron overload in non-transfusion-dependent thalassemia: 1-year results 
from a prospective, randomized, double-blind, placebo-controlled study. 
Blood. 2012;120(5):970–977.
3. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces 
iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 
1-year extension results from the THALASSA study. Ann Hematol. 2013; 
92(11):1485–1493.
4. Novartis Pharmaceuticals [webpage on the Internet]. EXJADE® (defera-
sirox) US Prescribing Information; 2015. Available from: http://www.
pharma.us.novartis.com/product/pi/pdf/exjade.pdf. Accessed August 31, 
2016.
5. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp 
Med Biol. 2002;509:185–203.
6. Steinhauser S, Heinz U, Bartholoma M, et al. Complex formation of 
ICL670 and related ligands with FeIII and FeII. Eur J Inorg Chem. 2004; 
21:4177–4192.
7. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in 
reducing and preventing cardiac iron overload in β-thalassemia. Blood. 
2010;115(12):2364–2371.
Drug Design, Development and Therapy 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4075
Efficacy and safety of iron chelation therapy in NTDT
 8. Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial 
of deferasirox versus deferoxamine for myocardial iron removal in beta-
thalassemia major (CORDELIA). Blood. 2014;123(10):1447–1454.
 9. Westwood MA, Anderson LJ, Maceira AM, et al. Normalized left ven-
tricular volumes and function in thalassemia major patients with normal 
myocardial iron. J Magn Reson Imaging. 2007;25(6):1147–1151.
 10. Pennell DJ, Carpenter J-P, Roughton M, Cabantchik IZ. On improve-
ment in ejection fraction with iron chelation in thalassemia major and 
the risk of future heart failure. Cardiovasc Magn Reson. 2011;13:45.
 11. Taher AT, Porter JB, Viprakasit V, et al. Approaching low liver iron bur-
den in chelated patients with non-transfusion-dependent thalassemia: the 
safety profile of deferasirox. Eur J Haematol. 2014;92(6):521–526.
 12. Al-Khabori M, Bhandari S, Al-Huneini M, Al-Farsi K, Panjwani V, 
Daar S. Side effects of deferasirox iron chelation in patients with beta 
thalassemia major or intermedia. Oman Med J. 2013;28(2):121–124.
 13. Karimi M, Arandi N, Haghpanah S, et al. Efficacy of deferasirox 
(Exjade(R)) in modulation of iron overload in patients with beta-
thalassemia intermedia. Hemoglobin. 2015;39(5):327–329.
 14. Ladis V, Berdousi H, Gotsis E, Kattamis A. Deferasirox administration 
for the treatment of non-transfusional iron overload in patients with 
thalassaemia intermedia. Br J Haematol. 2010;151(5):504–508.
 15. Voskaridou E, Plata E, Douskou M, et al. Treatment with deferasirox 
(Exjade) effectively decreases iron burden in patients with thalassae-
mia intermedia: results of a pilot study. Br J Haematol. 2010;148(2): 
332–334.
 16. Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost-utility 
analysis of deferasirox compared to standard therapy with desferrioxam-
ine for patients requiring iron chelation therapy in the United Kingdom. 
Curr Med Res Opin. 2008;24(6):1609–1621.
Drug Design, Development and Therapy 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4076
Taher et al
Author’s reply
George J Kontoghiorghes
Postgraduate research Institute of Science, Technology, 
environment and Medicine, Limassol, Cyprus
Correspondence: George J Kontoghiorghes
Postgraduate research Institute of Science, Technology, environment 
and Medicine, 3 Ammochostou Street, Limassol 3021, Cyprus
Tel +357 2627 2076
email kontoghiorghes.g.j@pri.ac.cy
Dear editor
There are many murky areas and marketing, legal, ethical, 
and other conflicts in the pharmaceutical industry, some of 
which involve physicians and academics. These activities 
and related ethical issues affect the safety and treatment 
of millions of patients.1–11 Irregular and sometimes illegal 
activities for new patented drugs carried out by pharmaceuti-
cal companies, such as secrecy agreements with academics/
academic institutions, can lead to biased reporting of the 
results of clinical trials and cover ups or underreporting of 
toxic side effects, as well as doctor’s bribes, irregularities in 
drug pricing, corruption of the drug regulatory authorities, 
influential medical journals and patient organizations, etc.1–11 
The commercial influence and drug marketing tactics by 
pharmaceutical companies in the case of deferasirox affect 
the safety and long-term survival of thousands of thalassemia 
and other categories of transfused patients.11–14
Misinformation on Exjade has recently reached the stage 
of criminal investigations and fines, eg, of US $60 million 
settlement of a civil fraud lawsuit for understating life-
threatening toxicities and US $45 million for false claim alle-
gations being submitted to federal health care programs.15–17 
Furthermore, one of the largest law suits ever faced by a 
pharmaceutical company of US $3.5 billion for damages and 
civil fines was filed against Novartis in 2015 by the FBI of 
the US government involving Exjade and Myfortic.15–17
Similarly, there are many misconceptions, inaccuracies, 
and omissions in the letter of Taher et al regarding the toxic-
ity, efficacy, and cost of Exjade in comparison to deferiprone 
and deferoxamine. Most of these issues have been extensively 
discussed in the past and reflect the commercial interference 
of pharmaceutical companies in academia, health authorities, 
medical literature, etc, all of which aim for the increase in 
sales of drugs.1–14,18–21
Taher et al omit to mention that the cause of fatal renal, 
hepatic, bone marrow, and hemorrhagic cases, as well 
as many other serious toxic side effects, including warn-
ings about aluminum coadministration with deferasirox, 
are included in the Exjade drug labels.18–21 There are also 
misconceptions by Taher et al, since there is no difference 
in the use of chelating drug protocols for thalassemia major, 
intermedia, “non-transfusion-dependent thalassemia”, and 
other similar categories of patients with equivalent levels of 
iron load. In this context, the recent approval for the use of 
Exjade in iron loaded non-transfusion-dependent thalassemia 
patients does not mean that these patients have not been 
receiving effective treatment in the past 50 years nor that these 
patients cannot be continuously and effectively treated using 
deferoxamine and deferiprone.22,23 Furthermore, the long-term 
effective and safe use of deferoxamine and deferiprone in 
iron loaded non-transfusion-dependent thalassemia patients 
outweighs any biased clinical trial results in a small number 
of deferasirox-treated patients controlled by Novartis.22,23
Major inaccuracies in the comments of Taher et al include 
the rate of mortality of 11.7% reported by the European 
Medicines Agency for deferasirox, whereas for deferoxamine 
and deferiprone it is ,0.1% in postmarketing surveillance 
including deaths in clinical trials.12,21 Furthermore and most 
importantly, substantial and rapid reduction or complete 
removal of toxic iron deposits, as well as elevation of left ven-
tricular ejection fraction is observed in deferiprone- or defer-
iprone/deferoxamine-treated thalassemia patients, whereas 
no such results are observed in deferasirox-treated patients, 
where such improvements are rare or even nonexistent.24,25 
The reduction or elimination of cardiac mortality since the 
introduction of deferiprone in thalassemia patients worldwide 
has increased the survival of thalassemia patients to near 
 normal life span levels, whereas the introduction of defera-
sirox is likely to reverse this improvement.13,26
Taher et al continue to mislead the medical community 
by reporting findings from Novartis-funded and -controlled 
clinical trials with deferasirox in thalassemia, which do not 
appear to be confirmed in clinical practice or by independent 
investigators.22,25,27 For example, only ~10% of thalassemia 
patients are using deferasirox in Cyprus, whereas the majority 
are using deferiprone either in combination with deferoxam-
ine or as a monotherapy.13,26
The recent increase in the maximum dose of deferasirox 
from 30 mg/kg/d to 40 mg/kg/d and its suggested use in 
non-transfusion-dependent thalassemia patients with serum 
ferritin ,300 ng/mL is a desperate attempt to improve the 
efficacy profile of deferasirox and its sales in comparison to 
deferiprone and deferoxamine. However, these changes may 
further increase the toxicity risks, especially since earlier 
animal studies and clinical reports have shown fatal or serious 
renal and other toxicities.
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In addition, there are misleading comments by Taher et al 
on the cost of deferasirox, which for example does not include 
any prophylactic renal and other clinical and biochemical 
tests for its toxicity, in comparison to deferoxamine and defer-
iprone. The high cost of deferasirox appears to affect patient 
treatment and safety, as well as government health budgets 
and the tax payers in general.11–14 In particular, the high retail 
price makes deferasirox unavailable in developing countries 
where the vast majority of thalassemia patients live.11–14
Taher et al are public employees receiving undisclosed 
payments from Novartis for the promotion of Exjade, which 
may be contrary to the public and patients’ interests.15–17 In con-
trast, in my case as the inventor of the generic drug deferiprone 
and other investigational new drugs, these inventions are all 
part of academic research, which is widely described in the 
medical and other literature with no commercial involvement 
or receipt of any related income. This information was also 
disclosed to the journal during the submission of the paper.12
The author reports no conflicts of interest in the published 
paper entitled “Efficacy and safety of iron-chelation therapy 
with deferoxamine, deferiprone, and deferasirox for the treat-
ment of iron-loaded patients with non-transfusion-dependent 
thalassemia syndromes”, wherefore a statement/disclosure 
was submitted to the journal Drug Des Devel Ther before 
publication, indicating that “I have made the following dis-
coveries: deferiprone (L1) and maltol iron28 and also other 
discoveries, eg, deferoxamine (DF) suppositories.29 I have 
also designed the combination of L1/DF30 and the ICOC 
protocol.31 I have also originally suggested the use of L1 in 
Friedreich ataxia, Parkinson’s, and Alzheimer’s diseases.32 
None of this work was supported by pharmaceutical or other 
commercial companies”. It should also be noted that the 
patent on the generic drug deferiprone expired over 10 years 
ago, and the author receives no income or consultancies or 
any other support by any commercial companies.
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